Use of chitin-based medicament for the treatment in milk teeth.

Evaluation of chitosan as a pulpotomy agent in primary molars- an in vivo study

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/08/035696

Enrollment

Registered

2021-08-16

Start date

Unknown

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K040- Pulpitis

Interventions

Intervention1: Chitosan: Axiostat which is the commercially available form of Chitosan will be used as a medicament for the pulpotomy procedure. Control Intervention1: Formocresol: Formoa-cresol is us

Eligibility

Inclusion criteria

Inclusion criteria: 1.Large carious lesion in an otherwise restorable primary tooth 2.No spontaneous pain. 3.More than two-thirds of the root length is still present 4.No sign of internal or external root resorption 5.Hemorrhage from the amputated pulp site is controlled within 5 minutes.

Exclusion criteria

Exclusion criteria: 1.Not fulfilling the above-mentioned clinical or radiographic criteria. 2.Inability to achieve hemostasis within 5 minutes of pressure application with a moist cotton pellet. 3.Bright red bleeding at the amputated pulp site.

Design outcomes

Primary

Measure	Time frame
This study aims to clinically and radiographically evaluate the success of Chitosan as a medicament for pulpotomy.Timepoint: 6 months	—

Secondary

Measure	Time frame
Chitosan can be used as an alternative to formocresol for pulpotomy procedure.Timepoint: 6 months	—

Countries

India

Contacts

Public ContactNidhish Krishna R

A B Shetty Memorial Institute of Dental Sciences

drnikitashanbhag@gmail.com9886875769

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026